Literature DB >> 2827379

Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.

J W Stave1, J L Card, D O Morgan, V N Vakharia.   

Abstract

Monoclonal antibodies (MAbs) were derived from mice infected with foot-and-mouth disease virus type O1 Brugge (FMDV 01B) or immunized with inactivated virions (140 S) or viral subunits (12 S). A total of 19 neutralizing MAbs were characterized of which 17 recognized conformationally determined epitopes and two recognized amino acid sequences on isolated VP1. Neutralizing MAbs were used to select antigenic variants of FMDV O1B. Based on cross-neutralization and binding assays with MAbs the variants were divided into discrete groups demonstrating the presence of three unique neutralization sites on FMDV O1B. One site was present only on intact 140 S virions, a second was present on both 140 S virions and 12 S subunits, and the third was present on 140 S virions, 12 S subunits, and isolated VP1. Comparison of the deduced nucleic acid sequence of parental FMDV O1B with those of the O1B variants demonstrated that the epitope recognized by the VP1-reactive, neutralizing MAbs included amino acid residues 138, 144, and 148. Cross-neutralization assays demonstrated that these neutralization sites of FMDV O1B function on other type O1 strains of FMDV.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2827379     DOI: 10.1016/0042-6822(88)90390-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  24 in total

1.  Foot-and-mouth disease virus O1Lombardy is biochemically related to O2 isolates.

Authors:  O Krebs; H G Berger; W Niedbalski; O Marquardt
Journal:  Virus Genes       Date:  1991-07       Impact factor: 2.332

2.  Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants.

Authors:  J C Saiz; M J Gonzalez; M V Borca; F Sobrino; D M Moore
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

3.  Nucleotide sequence of the P1 region of foot-and-mouth disease virus strain O1 Caseros.

Authors:  C Tami; G Kaplan; M E Piccone; E L Palma
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

4.  VP1-coding sequences of recent isolates of foot-and-mouth disease virus types A, O and Asia1.

Authors:  O Marquardt; B Haas
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

Review 5.  Development of foot-and-mouth disease virus strain characterisation--a review.

Authors:  R P Kitching; N J Knowles; A R Samuel; A I Donaldson
Journal:  Trop Anim Health Prod       Date:  1989-08       Impact factor: 1.559

6.  Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle.

Authors:  D Sa-Carvalho; E Rieder; B Baxt; R Rodarte; A Tanuri; P W Mason
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus.

Authors:  M G Mateu; M A Martínez; E Rocha; D Andreu; J Parejo; E Giralt; F Sobrino; E Domingo
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Mutations located on both F1 and F2 subunits of the Newcastle disease virus fusion protein confer resistance to neutralization with monoclonal antibodies.

Authors:  C Neyt; J Geliebter; M Slaoui; D Morales; G Meulemans; A Burny
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

9.  Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus.

Authors:  B Baxt; V Vakharia; D M Moore; A J Franke; D O Morgan
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

10.  Antigenic heterogeneity of a foot-and-mouth disease virus serotype in the field is mediated by very limited sequence variation at several antigenic sites.

Authors:  M G Mateu; J Hernández; M A Martínez; D Feigelstock; S Lea; J J Pérez; E Giralt; D Stuart; E L Palma; E Domingo
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.